BAP Officer Details

President

Professor Allan Young

Allan Young

King’s College London
President-elect until 2018; President until 2020; Past-President until 2022

Professor Allan Young holds the Chair of Mood Disorders and is Director of the Centre for Affective Disorders in the Department of Psychological Medicine in the Institute of Psychiatry at King’s College London, United Kingdom (UK). He has held academic appointments at Oxford University; Newcastle University (latterly holding the Chair of General Psychiatry at Newcastle), University of British Columbia in Vancouver, Canada, where he held the Leading Edge Endowment Fund Endowed Chair in Research in the Department of Psychiatry and was also the Director of the Institute of Mental Health, and Imperial College London, where he held the Chair of Psychiatry and was Director of the Centre for Mental Health.

Professor Young’s research interests focus on the cause and treatments for severe psychiatric illnesses, particularly mood disorders. He has received research grant funding from the UK Medical Research Council, the Wellcome Trust, the Stanley Medical Research Institute, the Canadian Institutes for Heath Research (CIHR), the National Institutes of Health (USA), and numerous other funding agencies. He has published over 300 peer-reviewed publications and a number of books about psychopharmacology and affective disorders including Bipolar Disorders: Basic Mechanisms and Therapeutic Implications (2nd Ed) with J.C. Soares, and Practical Management of Bipolar Disorder with I.N. Ferrier and E. Michalak (Cambridge University Press, 2010).

Professor Young is a member of a number of editorial boards and is a member of numerous professional and scientific societies. He is currently Past President of the International Society for Affective Disorders.

Declaration of Interests

  1. Have you, in the past three years, had patents or inventions from which you may derive personal benefit in the area of psychopharmacology?
  2. No
  3. Have you, in the past three years, had ownership or part ownership of a company with interests in the area of psychopharmacology? (This would include holding the shares of major companies in one's own name, or those of dependent family members.)
  4. No
  5. Have you, in the past three years, accepted a personal retainer from any company with an interest in psychopharmacology?
  6. No
  7. Have you, in the past three years, acted as a consultant to any company with an interest in psychopharmacology?
  8. No
  9. Have you, in the past three years, acted as an expert witness, either friendly or hostile, to any company with an interest in psychopharmacology?
  10. Acted as an expert witness to GSK
  11. Have you, in the past three years, held a research grant from any company with an interest in psychopharmacology?
  12. Janssen
  13. Have you, in the past three years, had membership of the speakers' bureau for any company?
  14. No
  15. Have you, in the past three years, accepted paid speaking engagements in industry supported symposia?
  16. Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders Astrazenaca, Eli Lilly, Janssen, Lundeck, Sunovion, Servier, Livanova
  17. Have you, in the past three years, accepted travel or hospitality NOT related to a speaking engagement?
  18. No
  19. Have you, in the past three years, recruited patients for industry-sponsored studies?
  20. Janssen
  21. If there is anything else you feel it necessary to disclose, please provide details below:
  22. Employed by King’s College London; Honorary Consultant SLaM (NHS UK) Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders Astrazenaca, Eli Lilly, Janssen, Lundeck, Sunovion, Servier, Livanova No share holdings in pharmaceutical companies Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study Investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK)

Form completed on 31st July 2018